🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Myeloablative Allogeneic Hematopoietic Cell Transplantation

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant NCT06315309Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: ATG Combined with Tacrolimus and Mini Methotrexate Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant NCT07709195Phase 21 site📍 Navi Mumbai Tata Memorial Centre · Tests: Sodium Copper Chlorophyllin Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients NCT04314219Phase 31 site📍 Riyadh King Faisal Specialist Hospital & Research Center · Tests: Cyclophosphamide 50mg, Methotrexate Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome NCT06128070Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) NCT06615050Phase 330 sites📍 Palo Alto📍 San Francisco📍 Miami Incyte Corporation · Tests: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF) Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) NCT06802315Phase 21 site📍 Chicago University of Illinois at Chicago · Tests: Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for… Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878NA1 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, None-placebo, Busulfan (BU) Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease NCT07029958Phase 41 site📍 Beijing Beijing Children's Hospital · Tests: recombinant humanized anti-CD25 monoclonal antibody Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation NCT05335434NA1 site📍 Boston Dana-Farber Cancer Institute · Tests: THOR LX2.3 with LED Lollipop Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies NCT05327023Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation NCT07249346Phase 23 sites📍 Birmingham📍 Boston📍 Columbus Hannah Choe, MD · Tests: Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy